UiPath (NYSE:PATH) Price Target Increased to $25.00 by Analysts at Wells Fargo & Company

UiPath (NYSE:PATH) had its price target raised by Wells Fargo & Company from $24.00 to $25.00 in a report issued on Thursday, Benzinga reports. The firm currently has an equal weight rating on the healthcare company’s stock.

PATH has been the topic of a number of other research reports. Mizuho lifted their target price on UiPath from $22.00 to $25.00 and gave the company a neutral rating in a report on Thursday. JPMorgan Chase & Co. raised UiPath from a neutral rating to an overweight rating and boosted their target price for the stock from $22.00 to $28.00 in a report on Thursday. William Blair initiated coverage on shares of UiPath in a report on Tuesday, January 2nd. They set an outperform rating on the stock. Barclays raised their price target on UiPath from $23.00 to $25.00 and gave the company an equal weight rating in a research report on Friday. Finally, Royal Bank of Canada raised their price objective on shares of UiPath from $27.00 to $29.00 and gave the stock a sector perform rating in a report on Thursday. Nine research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus target price of $27.13.

UiPath Stock Up 1.4 %

PATH traded up $0.32 on Thursday, hitting $23.07. 9,842,354 shares of the company traded hands, compared to its average volume of 10,074,664. The stock has a market capitalization of $13.06 billion, a PE ratio of -135.46 and a beta of 0.97. The company has a 50 day moving average of $23.52 and a 200-day moving average of $20.70. UiPath has a 12-month low of $12.38 and a 12-month high of $27.87.

Insider Activity at UiPath

In related news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $22.47, for a total transaction of $359,520.00. Following the completion of the sale, the chief financial officer now owns 103,505 shares in the company, valued at $2,325,757.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Ashim Gupta sold 16,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $22.47, for a total transaction of $359,520.00. Following the completion of the transaction, the chief financial officer now owns 103,505 shares of the company’s stock, valued at $2,325,757.35. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Rich Wong sold 200,000 shares of the firm’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $23.12, for a total value of $4,624,000.00. Following the sale, the director now owns 429,418 shares in the company, valued at approximately $9,928,144.16. The disclosure for this sale can be found here. Insiders have sold 411,000 shares of company stock valued at $9,418,670 over the last ninety days. Corporate insiders own 31.03% of the company’s stock.

Institutional Investors Weigh In On UiPath

Several institutional investors have recently bought and sold shares of PATH. Norges Bank purchased a new stake in UiPath during the 4th quarter valued at about $165,749,000. BlackRock Inc. lifted its holdings in UiPath by 32.1% in the 2nd quarter. BlackRock Inc. now owns 23,376,854 shares of the healthcare company’s stock worth $387,354,000 after buying an additional 5,681,577 shares during the period. Altimeter Capital Management LP lifted its holdings in UiPath by 175.4% in the 1st quarter. Altimeter Capital Management LP now owns 8,275,000 shares of the healthcare company’s stock worth $71,579,000 after buying an additional 5,270,194 shares during the period. Senvest Management LLC lifted its holdings in UiPath by 188.4% in the 2nd quarter. Senvest Management LLC now owns 6,027,933 shares of the healthcare company’s stock worth $99,883,000 after buying an additional 3,937,951 shares during the period. Finally, Millennium Management LLC raised its position in shares of UiPath by 899.5% in the 4th quarter. Millennium Management LLC now owns 4,049,999 shares of the healthcare company’s stock worth $51,475,000 after acquiring an additional 3,644,799 shares in the last quarter. 59.04% of the stock is currently owned by hedge funds and other institutional investors.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.